Inflation, Biosimilars, And The Wizard Of Oz: An Interview With Teva’s Christine Baeder
Executive Summary
The new chair of the US generics association talks to the Pink Sheet about how to make sure that policymakers don’t take the industry for granted.
You may also be interested in...
‘We Did Too Good Of A Job’ On Lowering Prices: Sandoz’s Haruvi Discusses Generic Sustainability
As Hatch-Waxman celebrates its 40th anniversary, the chair of the US generic trade association talks about striking the right balance on supply and pricing, preventing shortages, and improving Medicare price negotiations.
Departing Teva Exec Issues Warnings On Popular Shortage Solutions
Before leaving her role as Teva’s US generics COO, Christine Baeder discussed paying for quality, generic confidence, redundancy and predicting shortages.
US Generics Industry Group Gets New Board Chair, Begins Search For New CEO In Earnest
Christine Baeder’s departure from Teva means transition at the Association for Accessible Medicines’ board of directors as well; Sandoz’s Keren Haruvi becomes chair. The group also started looking for a new permanent CEO to replace Dan Leonard, who left AAM in December 2022.